Objective-VEGF (vascular endothelial growth factor-A) signaling to the endothelial cell (EC) through VEGFR2 (VEGF receptor-2) is the principal cue driving new blood vessel formation. FGD5 (faciogenital dysplasia-5)-a Rho-family guanine nucleotide exchange factor-is selectively expressed in EC. Deficiency of FGD5 is embryonically lethal in mice and perturbs angiogenesis and VEGF signal transduction. However, the mechanism of FGD5 regulation of VEGF signaling is poorly understood. Approach and Results-Angiogenic sprouting and EC cytoskeletal remodeling were evaluated in a 3-dimensional in vitro model. We examined the subcellular localization of FGD5 and VEGFR2 in EC by immunofluorescent staining and studied the association by immunoprecipitation.FGD5 deficiency reduced the number of angiogenic sprouts and tip cell filopodia by ≈80% and ≈70%, respectively. These defects were accompanied by downregulation of the expression of tip cell-specific markers. FGD5 inactivation led to a decrease in EC migration and early protrusion (lamellipodia) formation. In resting and VEGF-stimulated EC, FGD5 forms a complex with VEGFR2 and was enriched at the leading edge of the cell and among endosomes. FGD5 loss reduced mTORC2 (mammalian target of rapamycin complex-2)/Aktdependent cortactin activation downstream of VEGFR2 but did not alter VEGFR2 plasma membrane expression, Y1175 phosphorylation, or endocytosis. However, FGD5 loss decreased endosomal VEGFR2 coupling to phosphoinositide-3 kinase and diverted VEGFR2 to lysosomal degradation. Conclusions-FGD5 regulates VEGFR2 retention in recycling endosomes and coupling to PI3 (phosphoinositide-3) kinase/ mTORC2-dependent cytoskeletal remodeling. Visual Overview-An online visual overview is available for this article.
A ngiogenesis occurs during embryonic development to support tissue growth. In adults, angiogenesis is pivotal in physiological processes, such as wound healing and revascularization of ischemic tissue, and contributes to many pathologies, such as tumor growth and diabetic retinopathy. 1 Angiogenesis requires endothelial cell (EC) polarization in the direction of neovessel sprout extension, to form finger-like filopodia. 2 These filopodia characteristically mark the tip cell that will lead the migration and are thought to sense the proangiogenic cues that direct the EC migration path. 3 Tip cell filopodia mediate capillary extension and anastomoses between adjacent vessels in the formation of blood vessel networks. 4 Tip cells have a unique gene expression profile: they express relatively high levels of DLL4 (delta-like 4), VEGFR2 (vascular endothelial growth factor receptor-2), 3 ESM1 (endothelial specific molecule-1), 5 and CXCR4 (C-X-C chemokine receptor 4). 6 Hence both cytoskeletal remodeling and a gene transcription program characterize the angiogenic tip cell.
EC-specific growth factors and receptors drive EC differentiation into the tip cell. Of these, the best studied is VEGF (vascular endothelial growth factor-A) and its receptor VEGFR2. Phosphorylation of the VEGFR2 tyrosine residue Y1175/1173 recruits the PI3 (phosphoinositide 3) kinase signaling pathway 7 -an event critical to the development of new vessels. [8] [9] [10] The class IA PI3 kinases stimulated by VEGFR2 consist of a catalytic subunit and a regulatory subunit, 11 p85, that mediates the interaction of PI3 kinase with VEGFR2. 12, 13 The phosphorylated lipid product of receptor-stimulated PI3 kinase activity, PIP3 (phosphatidylinositide-3,4,5 trisphosphate), creates binding sites for the pleckstrin homology domains of PDK1 (phosphoinositide-dependent kinase 1) and Akt and is found on the plasma membrane and early endosomes.
14,15 Activated VEGFR2 is internalized by clathrin-dependent endocytosis, and then either degraded or recycled back to the plasma membrane. 16 VEGFR2 endocytosis is controlled by several Rabfamily GTPases. Rab5 regulates VEGFR2 internalization and transfer to early endosomes. 17, 18 Later, Rab4 and Rab11 will drive VEGFR2 recycling, whereas Rab7 will direct VEGFR2 to late endosomes and subsequently to degradation.
17 VEGFR2 continues to signal from within the endosomes, and the receptor trafficking among these endosome compartments can affect signal output from the receptor. [19] [20] [21] In polarized EC, receptor signaling from the plasma membrane or the endosome may initiate cytoskeletal remodeling involved in angiogenic sprouting. In the tip cell, filopodia arise from a cortical actin base. 22, 23 The cortical actin polymerization is initiated by the Arp (actin related protein) 2/3 complex, under the regulation of actin nucleation promoting factors. 24 One of these is cortactin, which activates Rac1 25 and in turn the Arp2/3 complex. Tyrosine phosphorylation of cortactin modulates cortactin activity, is involved in the migration of EC, 26, 27 and promotes VEGFR2-mediated angiogenesis. 28 Similarly, remodeling of the EC basement matrix contacts is required for EC movement and vessel formation. 29 FAK (focal adhesion kinase)-a nonreceptor tyrosine kinase enriched at matrix contact sites-critically regulates remodeling of these adhesion structures.
FGD5 (faciogenital dysplasia-5) is a member of the FYVE, Rho GTP/GDP exchange factor, and pleckstrin homology domain containing family. Although the family consists of 7 members (FGD1-6 and FARP2), FGD5 is selectively expressed in EC. 30, 31 Deletion of FGD5 expression results in early fetal loss, attributed to defective vascular development. 32, 33 The FYVE domain is predicted to mediate interactions with phosphatidylinositol-3′-phosphate 34 and suggests a role in endosomal trafficking. [35] [36] [37] In a previous report, we showed that FGD5 loss impairs angiogenesis and the activation of Akt. 30 However, a mechanistic understanding of the role FGD5 plays in VEGF-mediated angiogenesis and how it regulates the VEGF/PI3 kinase/Akt pathway has not been determined.
In the current article, we sought to study the function of FGD5 in the early events in angiogenesis and the role of FGD5 in the regulation of VEGFR2 signaling. We report a marked inhibition of VEGF-dependent angiogenic sprouting and filopodia formation after FGD5 loss among primary human EC spheroids. The resultant phenotype is accompanied by decreased expression of the tip cell markers DLL4, VEGFR2, and CXCR4. These defects in EC cytoskeletal remodeling are reflected in monolayer cultures as reduced EC migration and lamellipodia formation. We show that FGD5 is localized to the EC membrane ruffles, recycling endosomes, and complexes with VEGFR2 in EC. Further, FGD5 facilitates VEGFR2/PI3 kinase coupling on the endosome, regulates VEGFR2/PI3 kinase-dependent signaling to cortactin, and protects VEGFR2 from lysosomal degradation.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

FGD5 Deficiency Inhibits VEGF-Dependent Sprouting Angiogenesis and Tip Cell Specialization
To recapitulate tumor angiogenesis in vitro, we cocultured human umbilical vein EC-coated microcarrier beads with human renal cell carcinoma-coated beads in a 3-dimensional (3D) fibrin gel. We reduced the expression of FGD5 in the EC using RNA interference ( Figure 1A ). We observed EC sprouting stimulated by tumor cell-secreted angiogenic cues; however, the sprouting was markedly impaired among FGD5-deficient EC-coated beads ( Figure 1B and 1C) . Because VEGF potently induces angiogenesis, and angiogenic tip cells via the receptor VEGFR2, 3 we confirmed the effect of EC FGD5 loss on VEGF-dependent sprouting angiogenesis. Compared with nonspecific siRNA-treated controls, FGD5 loss lead to ≈80% decrease in the number of sprouts and shortened the formed sprouts by ≈20% ( Figure 1D and 1E) . Similarly, we examined the effect of FGD5 deficiency on filopodia formation in 3D culture. We found VEGF-stimulated filopodia formation was reduced by 70% among tip cells in the FGD5-deficient EC cultures ( Figure 1F and 1G) . Moreover, the length of the filopodia was reduced by ≈40% ( Figure 1G ). Similar findings were observed after FGD5 knockdown in HMEC-1 (human microvascular endothelial) cells ( Figure I in the online-only Data Supplement). These data indicate that FGD5 is required in VEGF-guided angiogenesis, and FGD5 loss is specifically associated with defective cytoskeletal remodeling during endothelial tip cell formation.
We investigated whether the defect in endothelial cytoskeletal remodeling because of FGD5 loss was accompanied by altered expression of endothelial tip cell-specific markers: VEGFR2, DLL4, CXCR4, and ESM1. First, to establish a model where the tip cell markers were highly induced, we compared 2-dimensional to 3D cell cultures. VEGFR2, CXCR4, and DLL4 were detected by Western blot among 2-dimensional cultures, but VEGF stimulation did not change their expression. In contrast, VEGF stimulation induced expression of these markers in 3D spheroid cultures ( Figure IIA and IIB in the online-only Data Supplement). To confirm these data, we isolated the RNA from the 3D EC cultures. Reverse transcription polymerase chain reaction analysis showed 4-fold increase in the abundance of DLL4, ESM1, and CXCR4 and 2-fold increase in VEGFR2 after VEGF stimulation ( Figure . These data show that FGD5 regulates the VEGF-stimulated increase in the expression of tip cell genes during 3D angiogenesis. Taken together with the observation of defective VEGF-stimulated cytoskeletal remodeling, the data suggest FGD5 loss impairs VEGF receptor coupling to signal transduction pathway(s) required to mediate these events.
FGD5 Regulates EC Migration and VEGFR2 Signaling to the Cytoskeleton
Endothelial migration is initiated by lamellipodia formation-a process dependent on actin polymerization. Of note, the activity of regulatory pathways for lamellipodia formation in monolayer cultures is highly correlated to migration in 3D cultures. 38 Thus, we sought to determine whether FGD5 loss is accompanied by migration defects in wounded EC monolayers. The polarized edge of the migrating ECs after VEGF stimulation revealed a striking defect in lamellipodia formation after FGD5 loss ( Figure IIIA in the online-only Data Supplement). The defect in lamellipodia formation in FGD5-deficient cells was comparable with Rac1-(an essential molecule for lamellipodia formation) deficient cells (Figure 2A and 2B) . 39, 40 Consistent with this observation, VEGF-stimulated closure of a scratch wound in a confluent EC monolayer was delayed among FGD5-deficient cells ( Figure 2C ; Figure This may contribute to the defects in sprout extension after FGD5 loss.
Next, we investigated the effect of FGD5 loss on VEGFR2-dependent downstream signals involved in cytoskeletal remodeling. We observed that FGD5 loss markedly decreased phosphorylation of FAK (P-FAK Y397 ; Figure 2D and 2E). Further, we observed the VEGF-stimulated phosphorylation of cortactin, a cortical actin binding protein, on Y421, which promotes lamellipodia formation, was reduced among FGD5-deficient EC ( Figure 2D and 2E) . 41 Thus the defect in lamellipodia formation evident as early as 10 minutes after polarizing the cells by the scratch wound was temporally correlated with the decrease in FAK and cortactin phosphorylation 10 minutes after VEGF stimulation ( Figure 2D and 2E). Further, in agreement with our previous report, 30 we found a reduction in Akt S473 phosphorylation ( Figure IV in the online-only Data Supplement). FAK Y397 phosphorylation after VEGF stimulation is dependent on PI3 kinase and mTORC2 (mammalian target of rapamycin complex-2) activity. 42 To determine whether the cortactin Y421 phosphorylation defect is linked to PI3 kinase/Akt signaling, we genetically targeted Akt1 with short interfering RNA and replicated the defect in cortactin Y421 phosphorylation after VEGF stimulation ( Figure 2F and 2G) .
To confirm the specificity of FGD5 knockdown on these events, we determined that FGD5 transgene expression rescued the effect of FGD5 knockdown in EC ( Figure IV in the online-only Data Supplement). These results suggest FGD5 regulates VEGFR2 coupling to PI3 kinase-dependent downstream signals in EC.
FGD5 Is Associated With the Leading Edge and Early Endosomes
Next, we studied FGD5 subcellular localization in ECs. ECs were stimulated with VEGF, and then immunostained for FGD5 and actin. FGD5 colocalized to the actin-rich lamellipodia and cytoplasmic structures ( Figure Figure 3A) . Similarly, reciprocal immunoprecipitation of VEGFR2 demonstrated association between VEGFR2, FGD5, and PI3 kinase p85 ( Figure 3B ). Taken together, these data suggest the FGD5/VEGFR2 complex might assemble at the cellular leading edge or directly after VEGFR2 is activated and undergoes endocytosis. Because activated VEGFR2 is targeted to early endosomes, 16 we sought to investigate FGD5 colocalization with early endosomes, marked by Rab5. ECs were stimulated with VEGF, and then fixed and immunostained for VEGFR2, FGD5, and Rab5 simultaneously. We observed that FGD5 was colocalized with both VEGFR2 and Rab5 ( Figure 3C ). These results indicate that FGD5 and VEGFR2 are complexed shortly after VEGFR2 activation and become internalized in a Rab5-positive early endosomal compartment.
Next, we sought to characterize the distribution of FGD5 among endosome compartments, that is, Rab4-, Rab11-, or Rab7-associated vesicles. VEGF-stimulated ECs showed marked colocalization of FGD5 with the recycling vesicles labeled with Rab4 or Rab11 after 30 minutes of stimulation ( Figure VIA and VIB in the online-only Data Supplement). FGD5 also colocalized to Rab7 vesicles but to a lower extent ( Figure VIA and VIB in the online-only Data Supplement). Thus, FGD5 is preferentially distributed among recycling endosomes. To confirm this observation, we examined FGD5 colocalization with the transferrin receptor-another marker for early and recycling endosomes. 43 As predicted, we found FGD5 colocalized with the transferrin receptor in VEGF-stimulated ECs ( Figure VII in the online-only Data Supplement).
It is known the VEGFR2 pool residing in the early endosomes is sorted either to Rab7 vesicles for degradation or Rab4/11 vesicles for recycling. 17, 44 Because we have shown that FGD5 is associated with VEGFR2 shortly after activation and is present among recycling endosomes, these data suggest that FGD5 could play a role in activated VEGFR2 endocytosis, trafficking, and coupling to PI3 kinase.
FGD5 Does Not Regulate VEGFR2 Activation or Endocytosis
To evaluate the effect of FGD5 loss on VEGFR2 activation, we studied VEGFR2 Y1175 phosphorylation. 7 After 10 minutes of VEGF stimulation, VEGFR2 Y1175 phosphorylation among FGD5-deficient ECs was unchanged compared with control ECs (Figure VIIIA and VIIIB in the online-only Data Supplement). Further, at later time points after stimulation with VEGF, the pattern of VEGFR2 Y1175 phosphorylation was similar among the control and FGD5-deficient ECs ( Figure VIIIC and VIIID in the online-only Data Supplement). This indicates intact VEGFR2 activity after FGD5 loss. However, we observed a decrease in the total VEGFR2 protein after VEGF stimulation among the FGD5-deficient ECs. Hence, we hypothesized that FGD5 loss alters VEGFR2 endocytosis and trafficking.
We studied the endocytosis of both the phosphorylated VEGFR2 Y1175 and the total VEGFR2. Flow cytometry analysis of surface membrane VEGFR2 expression showed a decrease in VEGFR2 after 1 hour of VEGF stimulation, indicating receptor endocytosis. However, ECs did not show any change in surface membrane VEGFR2 expression after FGD5 loss ( Figure VIIIE in the online-only Data Supplement). Next, we investigated phospho-VEGFR2 Y1175 colocalization with Rab5 or EEA1 (early endosome antigen 1), markers of early endosomes, 43 at 10 minutes after VEGF stimulation. The fraction of phospho-VEGFR2 Y1175 colocalized with early endosomes did not change among FGD5-deficient versus control ECs ( Figure IXA through IXD in the onlineonly Data Supplement). Taken together, FGD5 deficiency did not alter VEGFR2 availability or activation by VEGF, and activated VEGFR2 underwent prompt endocytosis, despite FGD5 loss.
FGD5 Loss Targets VEGFR2 to Lysosomal Degradation
FGD5 loss decreased the level of VEGFR2 by 25% and 50% at 30 and 60 minutes of VEGF stimulation, respectively ( Figure 4A and 4B ). This suggests that VEGFR2 is degraded more quickly in the absence of FGD5. The level of VEGFR2 was not appreciably changed by FGD5 knockdown in unstimulated cells ( Figure 4A ). To exclude an effect of FGD5 loss on VEGFR2 synthesis, we repeated the experiments in the presence of cycloheximide. FGD5 knockdown increased the loss of VEGFR2 both in unstimulated and VEGF-stimulated ECs ( Figure XA and XB in the online-only Data Supplement). We observed FGD5 loss did not affect VEGFR2 transcript abundance by polymerase chain reaction in unstimulated ECs (data not shown).
Because protein degradation occurs mainly through the lysosomal or proteasome pathway, we aimed to identify which system was involved in the increased degradation rate of VEGFR2 in the absence of FGD5. Treatment of human umbilical vein ECs with the lysosome inhibitor CA-074 (20 uM), 45 but not the proteasome inhibitor MG-132 (20 uM), 46 protected VEGRF2 from degradation after VEGF stimulation ( Figure 4C and 4D) . Similarly, CA-074, but not MG-132, rescued the accelerated degradation of VEGFR2 associated with FGD5 deficiency (Figure 4C and 4D) . Similar results were seen in HMEC-1 cells depleted of FGD5 ( Figure XI in the online-only Data Supplement). Consistent with this observation, we find that the fraction of VEGFR2 colocalized with Rab7 vesicles among FGD5-deficient ECs was more than double of that in the control ECs ( Figure XII in the onlineonly Data Supplement). Together, these lines of evidence indicate that VEGFR2 retention in early endosome compartments is mediated by FGD5.
FGD5 Is Required For Efficient VEGFR2 and PI3 Kinase Coupling
The early endosome compartment is a VEGFR2/PI3 kinase coupling site, and we detected both FGD5 and VEGFR2 complexed with p85 ( Figure 3B )-the regulatory subunit of PI3 kinase. Therefore, we hypothesized that FGD5 is required for VEGFR2/PI3 kinase coupling. After VEGF stimulation, we noticed a robust decrease in VEGFR2/p85 coupling by anti-VEGFR2 immunoprecipitation in FGD5-deficient ECs ( Figure 5A and 5B). Further, immunostaining showed markedly reduced p85 colocalization with phospho-VEGFR2 Y1175 in early endosomes among FGD5-deficient ECs ( Figure 5C and 5D). However, p85 coupling to phospho-VEGFR2 Y1175 at the membrane was intact ( Figure 5C ). Conversely, FGD5 loss does not compromise PI3 kinase coupling to FGFR1 (fibroblast growth factor receptor-1) or to a S1P (sphingosine 1-phosphate) receptor, other important proangiogenic growth factor receptors ( Figure XIII in the online-only Data Supplement). These results indicate that FGD5 is critical for VEGFR2/PI3 kinase coupling in the EEA1-positive early endosome compartments.
Because FGD5 loss is associated with accelerated VEGFR2 degradation via Rab7-positive late endosomes, we sought to determine whether interruption of trafficking to the Rab7-dependent degradation pathway 17 would rescue defective PI3 kinase signaling in FGD5-deficient cells. We observed that Rab7 knockdown in unstimulated ECs modestly increased Akt S473 phosphorylation ( Figure 6 ). Further, Rab7 loss partially rescued impaired Akt S473 phosphorylation Western blot after immunoprecipitating VEGFR2. Total cell lysate (TCL) shows the basal level of FGD5, VEGFR2, and p85. B, Quantification of p85 immunoprecipitated with VEGFR2 (n=3 independent experiments; *P<0.05 by Student t test). Control (siNS) or FGD5-deficient HUVECs (siFGD5) were starved overnight, stimulated with VEGF (30 ng/mL) for 10 min, and then fixed and stained for phospho-VEGFR2 Y1175 (P-VR2; green), p85 (red), EEA1 (cyan), and DAPI (blue). C, Representative images of P-VR2/EEA1/p85 colocalization in the cytosol (solid-frame boxes) and P-VR2/p85 colocalization on the plasma membrane (dashed-frame boxes). Arrows show P-VR2-positive EEA1 vesicles. Scale bar, 8 um. D, Quantification of the colocalization of p85 with the EEA1 vesicles by Pearson correlation. At least 45 cells per group were pooled from 3 different experiments (n=3 independent experiments; *P<0.05 by Student t test).
associated with FGD5 deficiency. These results indicate that FGD5 functions to maintain VEGFR2 signaling to PI3 kinase, in part, by retaining the VEGFR2/PI3 kinase signalsome in the early endosome and recycling endosome compartments.
Discussion
Proangiogenic signaling to the EC through the VEGF receptor-2 is critical for developmental angiogenesis and is a therapeutic target in the adult to block neoangiogenesis required for tumor growth. VEGFR2 coupling to the PI3 kinase pathway in the EC is essential to support new vessel development. In earlier work, we identified the endothelial-restricted Rho GTP-GDP exchange factor, FGD5, as a regulator of PI3 kinase pathway recruitment after VEGF stimulation. 30 In vivo, loss of VEGFR2, PI3 kinase-alpha, and FGD5 are each associated with failed embryonic vascular development and embryonic demise.
In the current work, we identify that loss of FGD5 induced by RNA interference in human ECs markedly impairs angiogenic sprouting to tumor cell-secreted growth factors or VEGF. FGD5 loss reduces filopodia and sprout extension from tip cells in 3D endothelial spheroid cultures and lamellipodia extension in monolayer culture. We link these events to VEGF-stimulated, PI3 kinase-dependent phosphorylation of FAK 47, 48 and cortactin, 26, 28 proteins known to regulate cytoskeletal remodeling, and show the pathway requires FGD5 expression. We demonstrate that VEGFR2, PI3 kinase, and FGD5 associate in a complex and localize the complex formation to the endosome compartment. Strikingly, FGD5 is required for stable recruitment of PI3 kinase to activated VEGFR2 and for VEGFR2 trafficking through recycling endosomes. In this way, FGD5 functions to shape VEGFR2 downstream signaling in the EC by modifying the signal output and the function of the receptor for sustained signal propagation to enable cytoskeleton remodeling.
VEGFR2 undergoes clathrin-mediated endocytosis after stimulation with VEGF and rapidly enters Rab5-and EEA1-positive endosomes. 17, 49, 50 A large fraction of the receptor is then recycled to the cell surface sequentially via Rab4 and Rab11 endosomes. Alternatively, the remaining VEGFR2 can be degraded by the proteasome or sorted from Rab5 or Rab4 through Rab7 endosomes for lysosomal degradation. 19, [51] [52] [53] Dysregulated trafficking of the activated receptor through these compartments impairs vascular development. 21, 54 After FGD5 loss, we observed no reduction in the cell-surface level of VEGFR2 assessed by flow cytometry. However, the overall abundance of VEGFR2 in the EC after receptor activation is decreased in the setting of FGD5 knockdown. Inhibition of lysosomal proteases rescues this effect of FGD5 loss on VEGFR2, suggesting FGD5 loss preferentially shunts VEGFR2 to the lysosomal degradation pathway. Consistent with this observation, FGD5 loss increases the fraction of VEGFR2 colocalized to Rab7-positive vesicles. Loss of Rab7 partially rescues the function of the activated VEGFR2 to recruit PI3 kinase/Akt signals, indicating FGD5 functions to retain VEGFR2 function in the recycling endosome compartments. Few regulators of this VEGF receptor sorting are known. NRP1 (neuropilin-1)-a coreceptor for VEGF-interacts with VEGFR2 and favors VEGFR2 transfer to recycling Rab11 endosomes. 19 Further, VEGFR2 deubiquitinylation by USP8 (ubiquitin specific peptidase 8) promotes VEGFR2 recycling and signaling. 53 Conversely, serine phosphorylation of the PEST domain of VEGFR2 and recruitment of PDCL3 (phosducin-like 3) are implicated to guide receptor trafficking toward the degradation pathway. 52, 55 The dephosphorylation and recycling of the activated VEGFR2 from the early endosome to the plasma membrane is a feature of VEGFR2 distinct from the degradation typical of other activated receptor tyrosine kinases in EC. 19 The molecular events relating FGD5 function to direct receptor sorting away from Rab7 vesicles requires further investigation. However, FGD5 represents an endothelialrestricted molecule specialized to guide the cell-type-specific adaptation of VEGFR2 endosomal storage and trafficking.
Internalization of VEGFR2 by endocytosis is known to promote stable, sustained signaling events. Activation of VEGFR2, reflected by Y1175 phosphorylation, is required to recruit PI3 kinase pathway signaling. 56, 57 The VEGFR2/ PI3 kinase coupling is found in Rab5 endosomes and is extinguished by the time VEGFR2 traffics to the Rab11 endosome. 19 Perturbation of endocytic trafficking of VEGFR2 is associated with altered signaling. For example, retention of VEGFR2 to the plasma membrane, by association with VE-cadherin, promotes receptor dephosphorylation. 50 Moreover, delayed endocytosis induced by loss of numb activity is also associated with decreased Akt phosphorylation, despite VEGF receptor activation. 58 Indeed, essential VEGFR2 signaling occurs from EEA1+ subcellular compartments, upstream of Rab11-or Rab7-labeled endosomes because knockdown of either Rab GTPase rescues the effect of disordered VEGFR2 traffic. 21 Signaling may even persist in the Rab7 endosome because lysosome pharmacological inhibition prolongs Akt phosphorylation. 51 Our data indicate the Rab5/EEA1-positive endosome is the principal subcellular location of the assembly of a VEGFstimulated PI3 kinase signaling complex involved in VEGFstimulated polarized remodeling of the cell cytoskeleton.
Spatial receptor signaling contributes to cell polarization and directed migration. We observe that FGD5 is enriched at the lead edge of the EC in subconfluent culture, and inhibition of polarized lamellae extension and monolayer wound closure occurs after FGD5 inactivation. Consistent with this impaired EC cytoskeletal remodeling, activation of both cortactin and FAK are impaired by FGD5 loss. We determine that both VEGF-stimulated cortactin and FAK activation requires PI3 kinase activity in the EC. 42 VEGF-stimulated recruitment of these molecules is dependent on engagement of the coreceptor NRP1 59, 60 and requires phospho-VEGFR2 Y1175-dependent PI3 kinase activity. 57 Loss of FGD5 does not affect phospho-VEGFR2 Y1175 endocytosis but decreases PI3 kinase association with the activated VEGFR2 in coimmunoprecipitation of whole cell lysates. Further, we provide direct evidence that FGD5 loss is associated with decreased recruitment of PI3 kinase, p85, to phospho-VEGFR2 Y1175 in the EEA1+ endosome. Taken together, these observations indicate polarized cytoskeletal remodeling events in the EC are dependent on early endosome assembly of PI3 kinase with VEGFR2 and recruitment of downstream mTORC2-dependent pathways. 42 In summary, we identify the function of FGD5 in regulation of tip cell-cytoskeletal remodeling in VEGF-guided sprouting angiogenesis. Moreover, we identify a novel role for FGD5 to regulate the coupling of PI3 kinase to activated VEGFR2 in the early endosome compartment and to retain VEGFR2 in recycling endosome compartments. These data indicate that FGD5 is a potential target to regulate pathological angiogenesis.
